{"id":"shr7280-simulant-ganirelix-acetate-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (erythema, pain, bruising)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Ovarian hyperstimulation syndrome (OHSS)"}]},"_chembl":{"chemblId":"CHEMBL5314377","moleculeType":"Protein","molecularWeight":"1690.45"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Ganirelix competitively blocks GnRH receptors in the pituitary gland, rapidly suppressing gonadotropin release without an initial flare effect. This prevents premature LH surge during controlled ovarian hyperstimulation, allowing precise timing of oocyte retrieval in assisted reproductive procedures.","oneSentence":"Ganirelix acetate is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:34:28.759Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART)"}]},"trialDetails":[{"nctId":"NCT05994378","phase":"PHASE3","title":"To Compare the Efficacy and Safety of Oral SHR 7280 Tablets With Ganirelix Acetate Injection in Infertile Female Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-08-29","conditions":"Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation","enrollment":317}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHR7280 simulant； Ganirelix Acetate Injection","genericName":"SHR7280 simulant； Ganirelix Acetate Injection","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ganirelix acetate is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. Used for Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}